PRVB.US Tender offer

Zest Acquisition Sub, Inc., a Delaware corporation (“Purchaser”) and an indirect wholly owned subsidiary of Sanofi, a French société anonyme, is offering to purchase all of the outstanding shares of common stock, par value $0.0001 per share, of Provention Bio, Inc., a Delaware corporation (the “company”), at a purchase price of $25.00 per Share in cash without interest and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions set forth in the Offer to Purchase and in the related letter of transmittal.

The terms of the offer are as follows:

Option 1: Take no action [Default option]

Option 2: USD 25 per share tendered and accepted（less any applicable withholding tax）

The deadline to tender shares to the offer will be 13/04/2023@ 16:00 (HONG KONG TIME GMT+8).

In the absence of an election, no action will be taken.

Please fill in the following information and use the registered email address of Futu to send an email to cs@futuhk.com.

1. Account Number:
2. Name: (In Chinese or English)
3. Stock code: PRVB.US
4. Options: (1) or (2)
5. Number of shares participating in corporate actions:

Note to applicants:
1. If shareholders holding 1 share or less of PRVB.US, they cannot participate in related corporate actions.
2. Option 1 is the default option. We will help clients to choose option 1 if have not received clients’ emails.
3. Once the relevant application is submitted, the stocks participating in the company's actions cannot be traded and the application cannot be withdrawn.
4. This corporate action does not accept additional applications, the maximum number of applications that a client can apply for does not exceed the number of eligible shares it holds.
5. The pending orders and unsettled shares will not be accepted for the time being.
6. Please confirm that the account funds are sufficient to pay the relevant fees of this corporate action. Otherwise, we will not bear any responsibility for the failure of your application.
7. If there is any update, all the information released by the listed company
shall prevail.

Helpful？

Yes No